tbuckley/cabot-search huggingface dataset:
Abstract 16786: Er71 Transcriptionally Activates Lmo2 and Regulates Endothelial Development
Authors: Junghun Kweon, Tara L Rasmussen, Xiaozhong Shi, Alicia Wallis, Kathy Bowlin, Michael Kyba, Naoko Koyano-Nakagawa, Daniel J Garry
Journal: Circulation (2011)

During early embryonic development, mesodermal progenitor cells give rise to multiple lineages including the cardiovascular, endothelial and hematopoietic lineages. Studies suggest that the extraembryonic yolk sac is a progenitor source for endothelial and hematopoietic lineages during embryogenesis. We have previously shown that Ets related protein 71(ER71) regulates the development of endothelial and hematopoietic lineages in the early yolk sac and embryo proper utilizing an ER71 gene knock out mouse model, an ER71 promoter driven EYFP-expressing transgenic mouse model and an doxycycline-inducible ER71-overexpressing ES/EB model. To decipher the ER71 mediated mechanism for lineage specification, we evaluated candidate downstream targets of ER71 using qPCR, transcriptome analysis, ChIP and transcriptional assays in the ER71 global gene knockout mouse and doxycycline inducible ER71 overexpressing ES/EB models. Using qPCR, we observed an absence of hematopoietic and endothelial restricted genes in the ER71 mutant yolk sacs and embryo proper compared to their wildtype littermates. We further observed a significant downregulation of Lmo2 in the mutant embryo compared to the wildtype control. Moreover, forced overexpression of ER71 using an inducible ES/EB system revealed that Lmo2 was significantly upregulated within 12 hours following ER71 induction. Analysis of approximately 100kb of the Lmo2 gene revealed multiple potential Ets binding motifs and evaluation of each of these sites using ChIP assays focused our efforts on the 1 kb region in the first intron of the Lmo2 gene. Using an array of biochemical techniques including EMSA, transcriptional assays and mutagenesis our data collectively support the hypothesis that Lmo2 is a direct downstream target of ER71. In summary, the present studies define an ER71-Lmo2 transcriptional network that governs endothelial specification and differentiation during cardiovascular development.
Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies
Authors: Jordon Jaggers, Heidi D. Klepin, Tanya M. Wildes, Rebecca L. Olin, Andrew S. Artz, Sarah A Wall, Samantha Jaglowski, Basem M. William, Don M. Benson, Ashley E. Rosko
Journal: Blood (2019)
Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia
Authors: Maher Albitar, Marina Y Konopleva, Ivan De Dios, Jeffrey Justin Estella, Spiraggelos Antzoulatos, Steven M. Kornblau, Antonio Cavazos, Sanam Loghavi, Koichi Takahashi, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood (2019)
Effect of Internet-Distributed HIV Self-tests on HIV Diagnosis and Behavioral Outcomes in Men Who Have Sex With Men
Authors: Robin J. MacGowan, Pollyanna R. Chavez, Craig B. Borkowf, S. Michele Owen, David W. Purcell, Jonathan H. Mermin, Patrick S. Sullivan
Journal: JAMA Internal Medicine (2019)

Undiagnosed HIV infection results in delayed access to treatment and increased transmission. Self-tests for HIV may increase awareness of infection among men who have sex with men (MSM).To evaluate the effect of providing HIV self-tests on frequency of testing, diagnoses of HIV infection, and sexual risk behaviors.This 12-month longitudinal, 2-group randomized clinical trial recruited MSM through online banner advertisements from March through August 2015. Those recruited were at least 18 years of age, reported engaging in anal sex with men in the past year, never tested positive for HIV, and were US residents with mailing addresses. Participants completed quarterly online surveys. Telephone call notes and laboratory test results were included in the analysis, which was completed from August 2017 through December 2018.All participants had access to online web-based HIV testing resources and telephone counseling on request. Participants were randomized in a 1:1 ratio to the control group or a self-testing (ST) group, which received 4 HIV self-tests after completing the baseline survey with the option to replenish self-tests after completing quarterly surveys. At study completion, all participants were offered 2 self-tests and 1 dried blood spot collection kit.Primary outcomes were HIV testing frequency (tested ≥3 times during the trial) and number of newly identified HIV infections among participants in both groups and social network members who used the study HIV self-tests. Secondary outcomes included sex behaviors (eg, anal sex, serosorting).Of 2665 participants, the mean (SD) age was 30 (9.6) years, 1540 (57.8%) were white, and 443 (16.6%) had never tested for HIV before enrollment. Retention rates at each time point were more than 54%, and 1991 (74.7%) participants initiated 1 or more follow-up surveys. More ST participants reported testing 3 or more times during the trial than control participants (777 of 1014 [76.6%] vs 215 of 977 [22.0%]; P < .01). The cumulative number of newly identified infections during the trial was twice as high in the ST participants as the control participants (25 of 1325 [1.9%] vs 11 of 1340 [0.8%]; P = .02), with the largest difference in HIV infections identified in the first 3 months (12 of 1325 [0.9%] vs 2 of 1340 [0.1%]; P < .01). The ST participants reported 34 newly identified infections among social network members who used the self-tests.Distribution of HIV self-tests provides a worthwhile mechanism to increase awareness of HIV infection and prevent transmission among MSM.ClinicalTrials.gov identifier: NCT02067039.
Longer Training for Radiographers
Authors: G. Osborne
Journal: BMJ (1964)

ments now taking place in this continent, significant differences are becoming obscured.It is suggested that details of the transfusion services throughout Africa should be col- lected and made available in pamphlet form to each co-operating service and to workers overseas who might be interested in having this information.This simple project should *prove to be of particular interest to those -workers who will be engaged in the Inter--national Biological Programme which will be ,commencing shortly.May I request, through the agency of your journal, that any transfusion service in Africa should send me the following information:(1) title of service; (2) address; (3) name of medical director; (4) area or region served; and (5) name of the responsible authority.It is hoped to obtain at least one address for each country.I would also be pleased to know of any organization or indi- vidual who may be interested in receiving copies of the information gathered from this survey.I am, etc.,
Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody
Authors: Ariel F Grajales-Cruz, Julio Chavez, Virginia Olivia Volpe, Jose Sandoval-Sus, Bijal Shah, Celeste Bello, Lubomir Sokol, Shanel Fisher, Rajesh R Nair, Yun Seongseok, Hayder Saeed, Leidy Isenalumhe, Elyce P. Turba, Lisa Nodzon, Javier Pinilla Ibarz
Journal: Blood (2019)
Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV
Authors: Kathryn Lurain, Ramya Ramaswami, Anaida Widell, Irene Ekwede, Jomy George, Maryalice Stetler-Stevenson, Mark Raffeld, Constance M. Yuan, Joseph Ziegelbauer, Frank Maldarelli, William D. Figg, Cody Peer, Seth M. Steinberg, Denise Whitby, Thomas S. Uldrick, Robert Yarchoan
Journal: Blood (2019)
Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms
Authors: Aishwarya Krishnan, Maria Pagane, Mikhail Roshal, Erin McGovern, Zoe Stone-Molloy, Janice Chen, Christopher Brooks, Ross L. Levine, Raajit K. Rampal
Journal: Blood (2019)
SELF-RETAINING ELECTROCARDIOGRAPHIC ELECTRODE
Authors: R. D. Haire
Journal: JAMA (1952)

<h3>To the Editor:—</h3> Recently, inThe Journal(<b>147</b>:1042 [Nov. 10]) mention was made in an article by Welsh of a self-retaining electrocardiographic electrode, which is an ingenious idea and solves most of the problems; however, in exercise tolerance tests and on extremely emaciated or hairy-chested persons, some difficulty may be experienced in using the Welsh electrode. In these cases a very useful device is the simple, homemade electrode holder that I described in<i>Southwestern Medicine</i>(<b>32</b>:55 [Feb.] 1951). This can be made from two strips of rubber cut from an old innertube, four clothespins, and a tongue blade.
Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
Authors: Eunice S. Wang, Elizabeth A. Griffiths, Roland B. Walter, Martin S. Tallman, Aaron D Goldberg, Boo Messahel, Richard M. Stone
Journal: Blood (2019)
HOUT-16. A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES BASED ON CONSOLIDATION REGIMENS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Authors: Savannah Gelhard, Amiee Maxwell, Adam Cohen, Joe Mendez
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Currently, Primary Central Nervous System Lymphoma (PCNSL) is treated with induction therapy consisting of polychemotherapy followed by consolidation therapy. Besides the incorporation of high-dose methotrexate as the backbone of induction therapy, there is no accepted standard induction or consolidation regimen for patients with PCNSL in the US. In this study, we compared three consolidation techniques by analyzing overall survival (OS) and progression free survival (PFS) in patients treated for PCNSL. METHODS Patients treated for newly diagnosed PCNSL at Huntsman Cancer Institute after July 1, 2012 with induction followed by consolidation therapy were retrospectively reviewed. Patients who completed one of the following regimens were included: rituximab/methotrexate/vincristine/procarbazine (R-MVP), rituximab/methotrexate/temozolomide (R-MT), or rituximab/methotrexate (R-M) for induction followed by consolidation with etoposide/cytarabine (EA), high-dose cytarabine (HIDAC), or autologous stem cell transplant (ASCT). Patients were excluded if there was evidence of systemic lymphoma on PET/CT or if the patient received radiation as consolidation therapy. Survival was calculated from the date of diagnosis and last date of known survival. RESULTS Twenty-three patients met eligibility criteria and received the following four treatment regimens: R-MT+EA (12), R-MT+ASCT (4), R-M+ASCT (1), and R-MVP+HIDAC (6). The median age of diagnosis was 61. Patients receiving ASCT (5) had a trend towards a more favorable OS (p=0.0675) compared to the other two consolidation therapies with no recurrence or death in those patients treated with ASCT. When comparing non-transplanted patients, R-MVP-HIDAC had a trend towards better OS and PFS compared to R-MT-EA. CONCLUSION This small retrospective review provides evidence that ASCT may be a superior treatment consolidation strategy in patients with PCNSL compared to EA and HIDAC, and that R-MT-EA may be less successful in practice than in published trials. These findings suggest that consolidation with ASCT should be strongly considered in all patients with PCSNL despite which induction therapy was received.
Genome Wide Interaction Analysis Identifies Expression Quantitative Trait Loci Associated with Reduced Survival after Reduced Intensity Conditioning HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant
Authors: Ezgi Karaesmen, Abbas A. Rizvi, Junke Wang, Michael Sovic, Qianqian Zhu, Li Yan, Leah Preus, Song Liu, Daniel Stram, Loreall Pooler, Xin Sheng, Christopher Haiman, David Van Den Berg, Amy Webb, Guy Brock, Stephen R. Spellman, Marcelo C. Pasquini, Philip L. McCarthy, Theresa E. Hahn, Lara E. Sucheston-Campbell
Journal: Blood (2019)
Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data of a Prospective Study in a Single Institution
Authors: Iván Murrieta-Álvarez, David P. Steensma, Juan Carlos Olivares-Gazca, Jesús Mauricio Olivares-Gazca, Andrés A. León-Peña, Yahveth Cantero-Fortiz, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Alejandro Ruiz-Argüelles, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Arguelles
Journal: Blood (2019)
Translational genomics of ovarian clear cell carcinoma
Authors: Saira Khalique, Christopher J. Lord, Susana Banerjee, Rachael Natrajan
Journal: Seminars in Cancer Biology (2019)

Ovarian clear cell carcinomas (OCCC) are rare aggressive, chemo-resistant tumours comprising approximately 13% of all epithelial ovarian cancers, which have distinct clinical and molecular features, when compared to other gynaecological malignancies. At present, there are no specific licensed targeted therapies for OCCC, although a number of candidate targets have been identified. This review focuses on recent knowledge underpinning our understanding of the pathogenesis of OCCC including direct and synthetic-lethal therapeutic strategies in particular focussing on ARID1A deficiency. We also discuss current targeted clinical trials and immunotherapeutic approaches.
Resident Duty Hour Reform and Mortality in Hospitalized Patients
Authors: Millard Bass
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Authors: Ting Liu, Huanling Zhu, Xuekun Yao, Yueying Peng, Yumei Wang, Guoning Zhan, Jing Yuan, Shaonan Ni, Jie Qiao, Zijian Hu, Cheng Lyu
Journal: Blood (2019)
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507
Authors: Adetola A. Kassim, Mark C. Walters, Mary Eapen, Brianne Allison, Adam M. Mendizabal, Robert A. Brodsky, Michael R. DeBaun
Journal: Blood (2019)
Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of pulmonary artery de-banding
Authors: Mario Boehm, Xuefei Tian, Yuqiang Mao, Kenzo Ichimura, Melanie J Dufva, Khadem Ali, Svenja Dannewitz Prosseda, Yiwei Shi, Kazuya Kuramoto, Sushma Reddy, Vitaly O Kheyfets, Ross J Metzger, Edda Spiekerkoetter
Journal: Cardiovascular Research (2019)

The temporal sequence of events underlying functional right ventricular (RV) recovery after improvement of pulmonary hypertension-associated pressure overload is unknown. We sought to establish a novel mouse model of gradual RV recovery from pressure overload and use it to delineate RV reverse-remodelling events.
Role of Acute Myeloid Leukemia Derived-Extracellular Vesicles in Dysregulating Normal Hematopoiesis
Authors: Ilaria Laurenzana, Stefania Trino, Daniela Lamorte, Michele Santodirocco, Lazzaro Di Mauro, Borazio Nazario, Antonella Caivano, Luciana De Luca, Pellegrino Musto
Journal: Blood (2019)
Increased Moraxella and Streptococcus species abundance after severe bronchiolitis is associated with recurrent wheezing
Authors: Jonathan M. Mansbach, Pamela N. Luna, Chad A. Shaw, Kohei Hasegawa, Joseph F. Petrosino, Pedro A. Piedra, Ashley F. Sullivan, Janice A. Espinola, Christopher J. Stewart, Carlos A. Camargo
Journal: Journal of Allergy and Clinical Immunology (2019)
Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019
Authors: Jaume Jorba, Ousmane M. Diop, Jane Iber, Elizabeth Henderson, Kun Zhao, Arshad Quddus, Roland Sutter, John F. Vertefeuille, Jay Wenger, Steven G.F. Wassilak, Mark A. Pallansch, Cara C. Burns
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Certification of global eradication of indigenous wild poliovirus type 2 occurred in 2015 and of type 3 in 2019. Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988 and broad use of live, attenuated oral poliovirus vaccine (OPV), the number of wild poliovirus cases has declined >99.99% (1). Genetically divergent vaccine-derived poliovirus* (VDPV) strains can emerge during vaccine use and spread in underimmunized populations, becoming circulating VDPV (cVDPV) strains, and resulting in outbreaks of paralytic poliomyelitis.† In April 2016, all oral polio vaccination switched from trivalent OPV (tOPV; containing vaccine virus types 1, 2, and 3) to bivalent OPV (bOPV; containing types 1 and 3) (2). Monovalent type 2 OPV (mOPV2) is used in response campaigns to control type 2 cVDPV (cVDPV2) outbreaks. This report presents data on cVDPV outbreaks detected during January 2018-June 2019 (as of September 30, 2019). Compared with January 2017-June 2018 (3), the number of reported cVDPV outbreaks more than tripled, from nine to 29; 25 (86%) of the outbreaks were caused by cVDPV2. The increase in the number of outbreaks in 2019 resulted from VDPV2 both inside and outside of mOPV2 response areas. GPEI is planning future use of a novel type 2 OPV, stabilized to decrease the likelihood of reversion to neurovirulence. However, all countries must maintain high population immunity to decrease the risk for cVDPV emergence. Cessation of all OPV use after certification of polio eradication will eliminate the risk for VDPV emergence.
Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCG)-ALL-2015
Authors: Xiaofan Zhu, Shuhong Shen, Jiaoyang Cai, Shaoyan Hu, Ju Gao, Hui Zhang, Yongjun Fang, Xiuli Ju, Xiaowen Zhai, Xuedong Wu, Changda Liang, Xin Tian, Qun Hu, Ningling Wang, Runming Jin, Hui Jiang, Lirong SUN, Minghua Yang, Kaili Pan, Chi Kong Li, Jun J. Yang, Cheng Cheng, JingYan Tang, Ching-Hon Pui
Journal: Blood (2019)
Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months
Authors: Christian Buske, Larry W Kwak, Wojciech Jurczak, Juan-Manuel Sancho, Edvard Zhavrid, Jin Seok Kim, Jose Angel Hernandez-Rivas, Aliaksandr Prokharau, Mariana Vasilica, Rajnish Nagarkar, Gayane Tumyan, Won-Seog Kim, Michinori Ogura, Sang Joon Lee, Sung Hyun Kim, Keum Young Ahn
Journal: Blood (2019)
Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study
Authors: Maria Luisa Lozano, Maria Eva Mingot-Castellano, María Perera, Isidro Jarque, Rosa Maria Campos, Tomás José González-López, Gonzalo Carreño Gomez-Tarragona, Nuria Bermejo, Maria Fernanda Lopez Fernandez, Aurora de Andrés, David Valcarcel, Felipe Casado, Teresa Álvarez Roman, María Isabel Orts, Silvana Novelli, Jose Ramon González-Porras, Estefanía Bolaños, Manuel Rodríguez López, Elisa Orna, Vicente Vicente Garcia
Journal: Blood (2019)
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)
Authors: Mirko Farina, Simona Bernardi, Nicola Polverelli, Camilla Zanaglio, Michele Malagola, Federica Re, Federica Cattina, Mariella D'Adda, Giuseppe Rossi, Tatiana Zollner, Andrew Dunbar, Ross L. Levine, Domenico Russo
Journal: Blood (2019)
Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib
Authors: Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Derek Tang, Angela Hu, Shien Guo, Weiqin Liao, Carrie Brownstein, Ruben A Mesa
Journal: Blood (2019)
Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction
Authors: Ply Chichareon, Rodrigo Modolo, Carlos Collet, Erhan Tenekecioglu, Maarten A. Vink, Pyung Chun Oh, Jung-Min Ahn, Carmine Musto, Luis S. Díaz de la Llera, Young-Seok Cho, Roberto Violini, Seung-Jung Park, Harry Suryapranata, Jan J. Piek, Robbert J. de Winter, Joanna J. Wykrzykowska, Christian Spaulding, Woong Chol Kang, Ton Slagboom, Sjoerd H. Hofma, Inge F. Wijnbergen, Emilio Di Lorenzo, Nico H. Pijls, Lorenz Räber, Salvatore Brugaletta, Manel Sabaté, Hans-Peter Stoll, Gregg W. Stone, Stephan Windecker, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2019)
A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation
Authors: Clara Chen, Philippe Armand, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, Greta Lozano-Ortega
Journal: Blood (2019)
P2.21 Clinical Responses and Survival in Hispanic Patients vs Non-Hispanic White Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy
Authors: D. Saravia, L. Raez, D. Sumarriva, R. Ruiz, T. Munoz Antonia, B. Hunis, D. Cress, L. Mas, P. Izquierdo, D. Kaen, S. Antonia, G. Lopes
Journal: Journal of Thoracic Oncology (2019)
Metabolic Aspects of Shock
Authors: Stanley M. Levenson
Journal: JAMA (1962)

WE DO NOT PLAN to describe all the metabolic changes which may result from shock but to make some general statements which express our philosophy regarding this problem and then to discuss briefly a few specific points. A detailed discussion of this subject has been presented elsewhere.<sup>1</sup>We will use the term "shock" to connote a syndrome whose central feature is a precarious state of the circulation resulting in an overall insufficiency of blood flow. This insufficiency, when prolonged, leads to variable and inadequate perfusion and nourishment of certain organs and tissues and ultimately results in their dysfunction. Are there specific metabolic disturbances which determine "irreversibility" and which lead inexorably to death from shock despite any treatment? This is the point, of course, that Dr. Bing has raised regarding myocardial function.<sup>2</sup>This general question and its corollary, namely, to what extent and how rapidly can the metabolic defects
Cytopenias in the Early Post-Autologous Hematopoietic Cell Transplantation (aHCT) Period Predict for Subsequent Development of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia (t-MDS/AML) Among Patients with Lymphoma
Authors: Liton Francisco, Can-Lan Sun, Patrick Halliday, Alysia Bosworth, Lindsey Hageman, Stephen J. Forman, Ravi Bhatia, Smita Bhatia
Journal: Blood (2014)